Managing BCG-Unresponsive Non–Muscle-Invasive Bladder Cancer (NMIBC): Clinical and Operational Perspectives : Episode 5
Opinion
Video
Gene Therapy Considerations for BCG-Unresponsive NMIBC
Author(s):
Key Takeaways
- BCG-unresponsive NMIBC is defined by persistent or recurrent high-grade tumors or carcinoma in situ after adequate BCG therapy.
- This condition requires alternative therapeutic strategies or radical cystectomy due to the failure of BCG treatment.
Katie S. Murray, DO, emphasizes the importance of administering newer treatments for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) locally by urologists, which helps reduce the overall burden on patients, minimizes systemic adverse effects, and eliminates the need for travel to specialized oncology centers, while also recommending strategies to encourage health care providers to adopt these treatments, including education on clinical trial data and real-world efficacy.
- From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss:
- Overall burden on patients
- Systemic adverse effects
- Travel to specialized centers
- What strategies would you recommend to encourage more health care providers to adopt newer treatment modalities for BCG-unresponsive NMIBC?
Related Videos
Related Content
